SCHEMBL1964956

SCHEMBL1964956

C[C@@]1(n2cnc3c(=O)[nH]c(N)nc32)O[C@H](CO)[C@@H](O)[C@@]1(C)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TK1 P04183 2/20 0.46
ADORA3 P0DMS8 1/20 0.45
PNP P00491 3/20 0.44
BLM P54132 2/20 0.44
USP2 O75604 1/20 0.44
TSHR P16473 1/20 0.44
EDNRA P25101 1/20 0.44
HTR2A P28223 1/20 0.44
RECQL P46063 1/20 0.44
HBB P68871 1/20 0.44
HSD17B10 Q99714 1/20 0.44
HPGD P15428 2/20 0.44
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
CYP3A4 P08684 1/20 0.43
NFKB1 P19838 1/20 0.43
VCP P55072 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28260991 0.90 TK1 (0.44) TK1ADORA3PNPBLMUSP2
SCHEMBL237755 0.87 HPGD (0.46) TK1ADORA3PNPBLMUSP2
SCHEMBL28747968 0.86 TK1 (0.44) TK1ADORA3PNPBLMUSP2
SCHEMBL1506536 0.85 POLB (0.51) PNPHPRT1
SCHEMBL28252469 0.85 TK1 (0.41) TK1ADORA3PNPBLMUSP2
SCHEMBL16555280 0.84 TK1 (0.44) TK1ADORA3PNPBLMUSP2
SCHEMBL30399088 0.84 TK1 (0.45) TK1ADORA3PNPBLMUSP2
SCHEMBL28707584 0.84 TK1 (0.46) TK1ADORA3PNPBLMUSP2
Guanosine SCHEMBL27082152 0.84 ADORA3 (0.58) ADORA3HPGDMEN1KMT2ASMN1; SMN2
SCHEMBL442605 0.83 ADORA3 (0.48) TK1ADORA3PNPBLMUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 312 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12584924-B2 Compositions and methods for diagnosing and treating chronic kidney disease SOCIETE DES PRODUITS NESTLE S.A. (CH) 2026-03-24 US claimed
CN-114373510-B Metabolic marker for diagnosing or monitoring lung cancer and screening method and application thereof 武汉迈特维尔医学科技有限公司 2023-12-01 CN claimed
WO-2023083197-A1 METABOLIC MARKER FOR DIAGNOSING OR MONITORING LUNG CANCER, AND SCREENING METHOD THEREFOR AND USE THEREOF 武汉迈特维尔医学科技有限公司 2023-05-19 WO claimed
CN-109425670-B Method for detecting fatigue degree of team based on human urine 中国民用航空局民用航空医学中心 2022-09-16 CN claimed
CN-109425669-B Method for screening biomarkers related to fatigue degree in human body fluid by liquid chromatography-mass spectrometry 中国民用航空局民用航空医学中心 2022-09-16 CN claimed
CN-114373510-A Metabolic marker for lung cancer diagnosis or monitoring and screening method and application thereof 武汉迈特维尔生物科技有限公司 2022-04-19 CN claimed
WO-2022075354-A1 A METHOD FOR OBTAINING AN INDEX FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE (AD) OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) 2022-04-14 WO claimed
CN-107607641-B Method for detecting mild and moderate fatigue degrees of civil aviation air traffic controller team 中国民用航空总局第二研究所 2020-09-08 CN claimed
EP-3529255-A1 TRINUCLEOTIDE MRNA CAP ANALOGS Arcturus Therapeutics, Inc. (US) 2019-08-28 EP claimed
US-20190101525-A1 METHOD FOR DETERMINING THE EXTENT OF AGING OF A SUBJECT AND TREATING THE SUBJECT TO SUPPRESS THE EXTENT OF AGING OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) 2019-04-04 US claimed
CN-109425670-A A method of teams and groups' degree of fatigue is detected based on human urine 中国民用航空局民用航空医学中心 2019-03-05 CN claimed
CN-108780099-A A kind of method, apparatus, system and kit for measuring degree of aging 学校法人冲绳科学技术大学院大学学园 2018-11-09 CN claimed
CN-108693268-A A kind of combination of metabolic marker object and its kit for predicting coronary heart disease prognosis 百迈康生物医药科技(广州)有限公司 2018-10-23 CN claimed
WO-2018075827-A1 TRINUCLEOTIDE MRNA CAP ANALOGS ARCTURUS THERAPEUTICS, INC. (US) 2018-04-26 WO claimed
CN-107607641-A Air traffic control person teams and groups are slight and the detection method of moderate degree of fatigue 中国民用航空总局第二研究所 2018-01-19 CN claimed
WO-2013177222-A1 METABOLITE BIOMARKERS FOR THE DETECTION OF LIVER CANCER PURDUE RESEARCH FOUNDATION (US) 2013-11-28 WO claimed
WO-2001085220-A1 LABELED NUCLEOSIDES AND METHOD FOR THEIR PREPARATION RNA-TEC N.V. (BE) 2001-11-15 WO claimed
WO-2026107144-A1 RNA SEQUENCE FOR EXPRESSING PROTEIN IN CARDIOMYOCYTES ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2026-05-21 WO disclosed
EP-0238672-A1 PROCESS FOR DEOXIDIZING ALCOHOL Yamasa Shoyu Kabushiki Kaisha (JP) 1987-09-30 EP disclosed
EP-0106894-B1 METHODS AND TEST KIT FOR DIAGNOSING CANCER IN HUMANS SRI INTERNATIONAL (US) 1986-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12584924-B2 Compositions and methods for diagnosing and treating chronic kidney disease GLS, AADAT, FGF23 TK1 1369/4885ADORA3 499/4885PNP 241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.